Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
Revenue (Most Recent Fiscal Year) | $1.19M |
Net Income (Most Recent Fiscal Year) | $-444.04M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.19 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -37638.01% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -70.93% |
Return on Assets (Trailing 12 Months) | -55.25% |
Current Ratio (Most Recent Fiscal Quarter) | 2.79 |
Quick Ratio (Most Recent Fiscal Quarter) | 2.70 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 1.47 |
Book Value per Share (Most Recent Fiscal Quarter) | $2.28 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.45 |
Earnings per Share (Most Recent Fiscal Year) | $-1.89 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.88 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 279.31M |
Free Float | 250.26M |
Market Capitalization | $3.31B |
Average Volume (Last 20 Days) | 4.24M |
Beta (Past 60 Months) | 0.62 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 10.40% |
Percentage Held By Institutions (Latest 13F Reports) | 77.03% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |